Global Wellness Strategies Forms Pharma Subsidiary

Focused on Clinical Trials

 Vancouver, British Columbia, November 17, 2022 – Global Wellness Strategies Inc. (CSE: GWS) (Frankfurt: O3X4) (OTCQB: GWSFF) (“Global” or the “Company”) a prospect generator that provides high growth companies with financial, operational, and management assistance focused in health and wellness announces the formation of a wholly owned pharma subsidiary focused on clinical trials.

“Real strategic capital market partnerships are essential to assist our clients in their progression to the next level with their organic growth. Forming a pharma subsidiary focused primarily on funding clinical trials is essential to our partners’ successes,” Stated Meris Kott, CEO, Global Wellness Strategies Inc.

Global Wellness acquired Shanti Therapeutics in 2022 and all share issuances for the acquisition have been completed. iNGENü a subsidiary of Australian leader Cannvalate is engaged as the CRO (clinical research organization) by the Company to conduct clinical trials for Shanti Therapeutics. The protocol is a single center, randomized crossover study to investigate the efficacy of MDMA vs placebo in a model of experimental pain in healthy adults. Shanti has a targeted research pathway to clinical success, with strong proprietary protection under its already submitted patent providing a method for the treatment or prevention of pain. Canada-based PharmAla Biotech is to supply MDMA for the Shanti Therapeutics upcoming clinical trial and will disclose receipt of MDMA shortly as the Company readies for its import permit to Australia.

Global Wellness brands broadened their Canadian footprint with provincial partnerships and received a notice of acceptance recently for three new SKUs from the Ontario Cannabis Store (OCS) for GWS and Sunshine State Tea products. The SKU bundles will be available in adult dispensaries in early 2023 in Ontario. The Company will file patents for their formulations and are researching a Contract Research Organization (CRO) in the UK to begin cannabis trials on these products.

Corporate Update:

The Company has appointed Meris Kott as CEO of Shanti Therapeutics as the team readies for the first human clinical trials in Melbourne, Australia.

The Medical Advisory board at Global Wellness welcomes the team of BioMed360 Solutions Corp to the company in conjunction with the formation of the pharma subsidiary. Since 2019, BM360 has been focused on identifying cutting edge biotech and medical technology platform solutions within the medical and pharmaceutical industries. Most recently, BioMed360 is engaging with clinical stage biotechnology companies entering human clinical trials for various diseases including diabetes and forms of cancer.

About Global Wellness Strategies:

Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.

For further information visit websites:

Or Contact Meris Kott CEO 604.484.0355 or email to [email protected]

Further information about the Company is available on under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.